The purpose of the Clinical Research Office (CRO) is to provide central management and oversight functions for coordinating, facilitating, and reporting on the cancer clinical research of the center, whatever the origin. The CRO accomplishes this purpose by providing the following services to Mayo Clinic Cancer Center (MCCC) investigators: 1) Protocol development and maintenance support, 2) Regulatory support, 3) Data systems management, 4) Quality control, 5) Operational support, and 6) Information systems. With centralized services, the CRO provides a stable and efficient administrative structure to coordinate these activities across the entire scope of the MCCC, including phase I-III clinical trials, pilot studies, and population-based studies. The Clinical Research Office previously functioned as part of the Mayo Clinic Cancer Center Statistics Unit Shared Resource. This shared resource was comprised of two units - the Statistics Unit and the Research Support Services Unit. Due to the recent significant expansion in scope and increase in regulatory burden, the two units have now separated, forming the Biostatistics Shared Resource and the Clinical Research Office. The CRO supports clinical trials and non-interventional population-based clinical research that are supported by one or more of the following: ? Peer-reviewed extramural funds (NIH, DoD, etc.), ? Mayo Clinic Cancer Center (including CCSG) ? Phase land Phase II (NCI, U01, N01) ? NCI Cooperative Group and CCOP Programs (MCCC is the research base of the North Central Cancer Treatment Group (NCCTG) and a member of ECOG, RTOG, GOG, ACoSOG, and COG) ? Industry funds The ability to use the same database for all studies and to configure tables, interfaces, and reports to meet program or protocol specific needs, allows the systems and procedures to be consistent between all sponsors and programs. This consistency fosters efficiency and programmatic operational synergy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-33
Application #
7414497
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$621,180
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320

Showing the most recent 10 out of 1129 publications